skip to Cookie NoticeSkip to contents

The health and safety of our patients, visitors and staff remains our top priority. Learn more about our Safe Care Commitment. For faster entry, use our Prescreen app prior to arrival.

Header Skipped.

The Program in Skin Toxicities from Anticancer Therapies

Dana-Farber/Brigham and Women's Cancer Center

The Program in Skin Toxicities from Anticancer Therapies provides urgent and longitudinal care for oncology patients suffering from dermatologic adverse effects due to anticancer therapies. Bridging institutions, the program offers dedicated oncodermatology clinics at Brigham Dermatology Associates and in the Center for Cutaneous Oncology at the Dana-Farber Cancer Institute. Our providers bring expert clinical care to patients with complications from targeted and cytotoxic chemotherapy, immunotherapy, radiation and stem cell transplantation.

Pediatric patients are seen in the Jimmy Fund Clinic. Together with our basic scientists, our experts research these adverse events in the skin and the most appropriate and effective ways to reduce them. Our clinicians work closely with the oncology teams at DFCI to improve patient quality of life while allowing patients to maintain the most effective anticancer regimen possible.

Our Locations

Our Experts


For over a century, a leader in patient care, medical education and research, with expertise in virtually every specialty of medicine and surgery.

About BWH